Congress Materials

Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Chiorean MV, Ha C, Armuzzi A, Lawendy N, Mundayat R, Salese L, Woolcott JC, Su C, Dotan I October 5, 2021 UEGW 2021 Ulcerative Colitis

Analysis of infections of interest in patients treated with tofacitinib in the ulcerative colitis clinical programme

View Presentation
Poster
Dubinsky MC, D'Haens GR, Sandborn WJ, Ng SC, Panés J, Su C, Lawendy N, Lazariciu I, Gardiner S, Mundayat R, Kulisek N, Modesto I, Torres J October 5, 2021 UEGW 2021 Ulcerative Colitis

Association between efficacy outcomes and prior duration of remission in patients with ulcerative colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study

View Presentation
Poster
Armuzzi A, Hart A, Sharma PP, Hoskin B, Woolcott J, Mammar N, Hennessy F, Cappelleri JC, Milligan G, Dignass A October 5, 2021 UEGW 2021 Ulcerative Colitis

Characteristics and real world treatment history of patients treated with tofacitinib for ulcerative colitis in Europe

View Presentation
Poster
Loftus Jr EV, Armuzzi A, Baumgart DC, Gecse KB, Connelly SB, Su C, Kwok KK, Guo X, Kinnucan JA October 5, 2021 UEGW 2021 Ulcerative Colitis

Clostridium difficile infection in patients treated with tofacitinib in the ulcerative colitis clinical programme

View Presentation
Poster
Lee SD, Allegretti JR, Steinwurz F, Connelly SB, Lawendy N, Paulissen J, Gecse KB October 5, 2021 UEGW 2021 Ulcerative Colitis

Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline endoscopic subscore

View Presentation
Oral Presentation
Winthrop KL, Melmed GY, Vermeire S, Panés J, Kulisek N, Mundayat R, Lawendy N, Su C October 5, 2021 UEGW 2021 Ulcerative Colitis

Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib: results from the Phase 2 and Phase 3 clinical programmes

View Presentation
Poster
Sandborn WJ, Dubinsky MC, Torres J, Vermeire S, Kotze PG, Su C, Lawendy N, Paulissen J, Mundayat R, Gardiner S, Kulisek N, Modesto I, D'Haens GR October 5, 2021 UEGW 2021 Ulcerative Colitis

Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with ulcerative colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study

View Presentation
Oral Presentation
Colombel J-F, Osterman MT, Ibanez P, Vermeire S, Irving PM, Gardiner S, Connelly SB, Mundayat R, Lawendy N, Su C, Reinisch W October 5, 2021 UEGW 2021 Ulcerative Colitis

Maintenance of remission with tofacitinib in patients with ulcerative colitis: final results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open

View Presentation
Poster
D'Haens GR, Dubinsky MC, Regueiro M, Santana GO, Torres J, Kulisek N, Gardiner S, Mundayat R, Paulissen J, Lawendy N, Su C, Modesto I, Sandborn WJ October 5, 2021 UEGW 2021 Ulcerative Colitis

Non-invasive predictors of maintaining remission in patients with moderately to severely active ulcerative colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study

View Presentation
Oral Presentation
Hudesman DP, Torres J, Salese L, Woolcott JC, Mundayat R, Su C, Mosli MH, Allegretti JR October 5, 2021 UEGW 2021 Ulcerative Colitis

Patient-reported outcome improvement with tofacitinib in the ulcerative colitis OCTAVE clinical programme

View Presentation